SEC Company Response from Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — Jan 20, 2016
Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: Jan. 20, 2016 · CIK: 0000876343 · Accession: 0001140361-16-048268
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-209000
Letter
BIOTIME, INC.
1301 Harbor Bay Parkway, Suite 100
Alameda, California 94502
(510) 521-3390
January 21, 2016
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
RE:
BioTime, Inc.
Registration Statement on Form S-3
File No. 333-209000
Ladies/Gentlemen:
BioTime, Inc. (the “Company”) hereby requests that its Registration Statement on Form S-3, File No. 333-209000, be declared effective at 10:00 a.m. on January 25, 2016 or as soon thereafter as practicable.
The registrant acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
BioTime, Inc.
Show Raw Text
CORRESP 1 filename1.htm BIOTIME, INC. 1301 Harbor Bay Parkway, Suite 100 Alameda, California 94502 (510) 521-3390 January 21, 2016 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 RE: BioTime, Inc. Registration Statement on Form S-3 File No. 333-209000 Ladies/Gentlemen: BioTime, Inc. (the “Company”) hereby requests that its Registration Statement on Form S-3, File No. 333-209000, be declared effective at 10:00 a.m. on January 25, 2016 or as soon thereafter as practicable. The registrant acknowledges that: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, BioTime, Inc. By: s/Russell Skibsted Chief Financial Officer